Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus

European Journal of Clinical Investigation

Volumn 39, Issue 3, 2009, Pages 200-203

  Dullaart, R P F ^a   De Vries, R ^a   Voorbij, H A M ^a,b   Sluiter, W J ^a   Van Tol, A ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Arylesterase activity; Bezafibrate; HDL cholesterol; Paraoxonase 1; Simvastatin; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; BEZAFIBRATE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; MALE; MIDDLE AGED; SIMVASTATIN; STATISTICS AS TOPIC;

EID: 61349195857     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02090.x     Document Type: Article

References (18)

1. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004 15 : 399 404.
2. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity and minimally oxidized low density lipoprotein. J Clin Invest 1995 96 : 2882 91.
3. Mackness B, Durrington O, McElduff P, Yarnell J, Azam N, Watt M et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003 107 : 2775 9.
4. Troughton JA, Woodside JV, Yarnell JW, Arveller D, Amouyel P, Ferrières J et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 2008 197 : 556 63.
5. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998 139 : 341 9.
6. Dullaart RPF, de Vries R, Sluiter WJ, Voorbij HA. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol 2008 70 : 221 6.
7. Tomás M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000 20 : 2113 9.
8. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003 23 : 2083 9.
9. Bergheanu SC, van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, van der Bom JG et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL cholesterol. Curr Med Res Opin 2007 23 : 2235 40.
10. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008 66 : 366 74.
11. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998 138 : 217 25.
12. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M. Effect of fibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 2008 196 : 122 8.
13. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003 63 : 945 56.
14. van Himbergen TM, Roest M, de Graaf J et al. Indications that paraoxonase-1 contributes to high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005 46 : 445 51.
15. Gavish D, Leibovitz E, Shapira I. Rubinstein. Bezafibrate and simvastatin combination therapy for diabetic dyslipidemia: efficacy and safety. J Int Med 2000 247 : 563 9.
16. Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 2001 27 : 604 10.
17. Zhou H, Tan KCB, Shiu SWM, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2007 23 : 927 33.
18. van Wijk J, Coll B, Castro Cabezas M et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 2006 33 : 1134 7.